Specific therapies include remdesivir, anti-interleukin-6 receptor antibodies, Janus kinase inhibitors [28, 29] as well as the microtubule disruptor sabizabulin [30] which has shown promising results in a recent phase II clinical trial in reducing mortality and respiratory failure. This evidence concerns the gene IL6R and respiratory failure.